I-Tirzepatide liyeza elinoveli elimele impumelelo enkulu kunyango lwe-2 yeswekile kunye nokukhuluphala. Yi-agonist yokuqala emibini ye-glucose-exhomekeke kwi-insulinotropic polypeptide (GIP) kunye ne-glucagon-like peptide-1 (GLP-1) receptors. Le ndlela ekhethekileyo yesenzo ibeka ngaphandle kweendlela zonyango ezikhoyo kwaye yenza imiphumo enamandla kulawulo lwe-glucose yegazi kunye nokunciphisa ubunzima.
Ngokusebenzisa i-GIP kunye ne-GLP-1 i-receptors, i-Tirzepatide iphucula i-insulin secretion kunye novelwano, iyanciphisa ukukhutshwa kweglucagon, icotha ukukhupha isisu, kwaye iyancipha ukutya.
Ilawulwa njengenaliti ye-subcutaneous kanye ngeveki, i-Tirzepatide ibonise ukusebenza okuphawulekayo kwizilingo zeklinikhi. Iphucula kakhulu ulawulo lwe-glycemic kunye nokunciphisa ubunzima bomzimba, ngokuphindaphindiweyo ukugqithisa ukusebenza kwamayeza akhoyo ngoku. Ukongezelela, izibonelelo ezinokuthi zenzeke kwi-cardiovascular ziye zabonwa.
Ezona ziphumo bezingalindelekanga zixhaphake sisisu esiswini, kubandakanywa isicaphucaphu, urhudo, nokugabha, okukholisa ukuthotywa ukuya kumodareyitha ngokuqatha kwaye kudla ngokuncipha ngokuhamba kwexesha.
Ngokubanzi, ukuphuhliswa kweTirzepatide kuphawula umda omtsha kunyango lwezifo ze-metabolic, ukubonelela ngesixhobo esinamandla sokulawula isifo seswekile kunye nokutyeba.
Ixesha lokuposa: Sep-01-2025